Economic Evaluation of PCSK9 Inhibitors in Reducing Cardiovascular Risk from Health System and Private Payer Perspectives.
about
Cost-effectiveness of Evolocumab Therapy for Reducing Cardiovascular Events in Patients With Atherosclerotic Cardiovascular Disease.Cholesterol Management in the Era of PCSK9 Inhibitors.Real-world use of PCSK-9 inhibitors by early adopters: cardiovascular risk factors, statin co-treatment, and short-term adherence in routine clinical practice.Limitations of traditional health technology assessment methods and implications for the evaluation of novel therapies.Updated Cost-effectiveness Assessments of PCSK9 Inhibitors From the Perspectives of the Health System and Private Payers: Insights Derived From the FOURIER Trial.'Highest risk-highest benefit' strategy: a pragmatic, cost-effective approach to targeting use of PCSK9 inhibitor therapies.
P2860
Economic Evaluation of PCSK9 Inhibitors in Reducing Cardiovascular Risk from Health System and Private Payer Perspectives.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh
2017年學術文章
@zh-hant
name
Economic Evaluation of PCSK9 I ...... nd Private Payer Perspectives.
@ast
Economic Evaluation of PCSK9 I ...... nd Private Payer Perspectives.
@en
type
label
Economic Evaluation of PCSK9 I ...... nd Private Payer Perspectives.
@ast
Economic Evaluation of PCSK9 I ...... nd Private Payer Perspectives.
@en
prefLabel
Economic Evaluation of PCSK9 I ...... nd Private Payer Perspectives.
@ast
Economic Evaluation of PCSK9 I ...... nd Private Payer Perspectives.
@en
P2093
P2860
P1433
P1476
Economic Evaluation of PCSK9 I ...... nd Private Payer Perspectives.
@en
P2093
Alejandro Arrieta
Emir Veledar
Timothy F Page
P2860
P304
P356
10.1371/JOURNAL.PONE.0169761
P407
P577
2017-01-12T00:00:00Z